SCHEMBL3485565

SCHEMBL3485565

CC(C)(C)NC(=O)Cn1c(-c2ccc(OC(F)(F)F)cc2)cc2cc(C(C)(C)C(=O)O)cc(Br)c21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 6/20 0.48
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
CACNA1B Q00975 2/20 0.41
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35
SHMT2 P34897 1/20 0.35
PDE2A O00408 1/20 0.34
ACLY P53396 2/20 0.34
GCGR P47871 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3485492 0.93 NR1I2 (0.55) NR1I2ALDH1A1GAACACNA1BTP53
SCHEMBL13401027 0.90 NR1I2 (0.50) NR1I2ALDH1A1GAACACNA1BNPC1
SCHEMBL3486003 0.90 ALDH1A1 (0.47) NR1I2ALDH1A1GAACACNA1BTP53
SCHEMBL8150072 0.82 NR1I2 (0.55) NR1I2ALDH1A1GAACACNA1BTP53
SCHEMBL12945190 0.79 NR1I2 (0.60) NR1I2ALDH1A1GAACACNA1BTP53
SCHEMBL3485683 0.77 NR1I2 (0.74) NR1I2ALDH1A1GAACACNA1BTP53
SCHEMBL8151113 0.72 NR1I2 (0.61) NR1I2ALDH1A1GAACACNA1BSMN1; SMN2
SCHEMBL8150104 0.70 NR1I2 (0.73) NR1I2ALDH1A1GAACACNA1BACLY
SCHEMBL21023417 0.69 NR1I2 (0.55) NR1I2ALDH1A1GAACACNA1BNPC1
SCHEMBL8152069 0.67 CACNA1B (0.59) NR1I2ALDH1A1CACNA1BSMN1; SMN2ACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087446-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK SHARP & DOHME CORP. 2010-04-08 US disclosed
EP-2150112-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS Merck & Co., Inc. (US) 2010-02-10 EP disclosed
WO-2008133867-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK & CO., INC. (US) 2008-11-06 WO disclosed
WO-2008133867-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK & CO., INC. (US) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087446-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, CACNA1S, TRPV2 NR1I2 1761/4885ALDH1A1 541/4885GAA 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.